Proactive Investors - Run By Investors For Investors

Arix Bioscience to invest another US$5mln in Autolus

Autolus said earlier this week it was looking to raise money from investors, and it has today confirmed plans to raise US$100.8mln through the issue of 4.2mln shares at US$24 each
Arix’s investment keeps its total stake in Autolus at 7.6%

Biotech investor Arix Bioscience PLC (LON:ARIX) has agreed to invest another £3.8mln (US$5.0mln) in Autolus Therapeutics PLC (NASDAQ:AUTL).

The share purchase will keep Arix’s stake in Autolus at 7.6%, which is valued at £62.6mln.

READ: Arix Bioscience confirms Autolus to launch proposed public offering

In total, Autolus is raising US$100.8mln from investors through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

“Our investment in Autolus today demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital,” said chief executive Joe Anderson.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

Arix backing its winners

“Arix first invested £10mln into Autolus's Series B round in March 2016,” noted analysts at US investment bank Stifel.

“Subsequent financing rounds, the Nasdaq IPO in June 2018 and now this latest equity offering, means Arix has invested £24.6mln so far into Autolus.

“That investment is now valued at £62.6m generating a decent return so far, but with the market effectively discounting the shares during the offering (shares sold at US$24 per ADS vs US$31 per ADS before the offer was announced), we would expect the shares to recover and provide greater value uplift for Arix.”

Arix shares were down 1.3% to 144.1p on Thursday morning.

--Adds analyst comment--

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin
healthy gut
Here we take a look at AIM-listed life sciences group, OptiBiotix Health

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use